A detailed history of Efg Asset Management (North America) Corp. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 8,091 shares of VRTX stock, worth $3.21 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares
8,091
Previous 8,439 4.12%
Holding current value
$3.21 Million
Previous $3.96 Million 4.88%
% of portfolio
0.64%
Previous 0.7%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$460.0 - $505.78 $160,080 - $176,011
-348 Reduced 4.12%
8,091 $3.76 Million
Q2 2024

Jul 25, 2024

BUY
$392.81 - $485.53 $447,017 - $552,533
1,138 Added 15.59%
8,439 $3.96 Million
Q1 2024

May 13, 2024

SELL
$407.69 - $446.08 $15,899 - $17,397
-39 Reduced 0.53%
7,301 $3.05 Million
Q4 2023

Feb 08, 2024

BUY
$343.0 - $410.68 $858,186 - $1.03 Million
2,502 Added 51.72%
7,340 $2.99 Million
Q3 2023

Nov 02, 2023

SELL
$338.18 - $362.46 $62,901 - $67,417
-186 Reduced 3.7%
4,838 $1.68 Million
Q2 2023

Jul 28, 2023

BUY
$314.42 - $351.91 $227,011 - $254,079
722 Added 16.78%
5,024 $1.77 Million
Q1 2023

Apr 27, 2023

SELL
$283.23 - $323.1 $32,004 - $36,510
-113 Reduced 2.56%
4,302 $1.36 Million
Q4 2022

Feb 03, 2023

BUY
$285.76 - $321.48 $128,877 - $144,987
451 Added 11.38%
4,415 $1.27 Million
Q3 2022

Oct 28, 2022

BUY
$273.83 - $305.53 $260,412 - $290,559
951 Added 31.56%
3,964 $1.15 Million
Q2 2022

Aug 04, 2022

BUY
$234.96 - $292.55 $707,934 - $881,453
3,013 New
3,013 $849,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.